Adjuvant Therapy for High-risk Endometrial Carcinoma

• Published in: Clinical oncology (Royal College of Radiologists (Great Britain)) 2021-09, Vol.33 (9), p.560-566
• Main Authors: Perera, J., Hoskin, P.
• Format: Article
• Language: English
• Subjects: Chemoradiation; chemotherapy; endometrium; high risk; molecular classification; radiotherapy
• ISSN: 0936-6555; 1433-2981
• DOI: 10.1016/j.clon.2021.05.009

About one-fifth of endometrial cancers are ‘high risk’, which carries a poorer prognosis. Management strategies to optimise their survival have been under investigation for many years. Despite recent advances, their overall survival remains relatively poor. The definition of high risk in endometrial cancers has been based on clinicopathological factors until recently, when molecular profiling has shown greater discrimination. There is, however, poor correlation between traditional clinicopathological factors and their molecular profile. This is the subject of ongoing trials to better individualise adjuvant post-hysterectomy treatment. The management of high-risk tumours is traditionally based on surgery followed by radiotherapy, despite no proven overall survival benefit in early stages. The place of chemotherapy remains under investigation, with recent trials showing benefit in more advanced stages. The Post Operative Radiation Therapy in Endometrial Carcinoma (PORTEC) and Gynecologic Oncology Group trials support the use of chemoradiation and chemotherapy for stage III and adverse histological subgroups. In addition, there is now early evidence of correlation between benefit from adjuvant chemotherapy based on molecular alterations in the tumour cells. In this review, we look at the current evidence on management strategies in the evolving era of molecular diagnosis and stratification.